Literature DB >> 10530686

Nonepileptic uses of gabapentin.

L Magnus1.   

Abstract

For decades, antiepileptic drugs (AEDs) have been used to treat a variety of nonepileptic conditions such as chronic pain, psychiatric disorders, and movement disorders. As indicated by recent published reports, gabapentin, a relatively new AED, is useful for treating a wide range of neurologic and psychiatric conditions. Although its exact mechanism of action has yet to be determined, gabapentin is likely to have multiple effects. Unlike conventional AEDs used to treat nonepileptic disorders (e.g., carbamazepine, phenytoin, valproate) gabapentin offers the advantages of low toxicity and a favorable side-effect profile. The largest area of nonepileptic use of gabapentin is neuropathic pain, in which it has demonstrated efficacy in treatment of postherpetic neuralgia, diabetic neuropathy, and trigeminal neuralgia. It has also been reported effective as therapy for several psychiatric disorders, most notably bipolar disorder. In addition, review of the published literature reveals the usefulness of gabapentin in movement disorders, migraine prophylaxis, and cocaine dependence. Future clinical studies will provide further insight into the range of conditions for which gabapentin is effective.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530686     DOI: 10.1111/j.1528-1157.1999.tb00936.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  18 in total

1.  Treatment of painful sensory neuropathy with tiagabine: a pilot study.

Authors:  V Novak; R Kanard; J T Kissel; J R Mendell
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

2.  Effect of Gabapentin on Sleep and Event-Related Oscillations (EROs) in Rats Exposed to Chronic Intermittent Ethanol Vapor and Protracted Withdrawal.

Authors:  Manuel Sanchez-Alavez; Derek N Wills; Leslie Amodeo; Cindy L Ehlers
Journal:  Alcohol Clin Exp Res       Date:  2018-01-31       Impact factor: 3.455

Review 3.  WITHDRAWN: Gabapentin for acute and chronic pain.

Authors:  Philip J Wiffen; Henry J McQuay; Jayne Edwards; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

4.  Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones.

Authors:  K G Sutton; D J Martin; R D Pinnock; K Lee; R H Scott
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes.

Authors:  A A Parsons; S Bingham; P Raval; S Read; M Thompson; N Upton
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  PD-0200347, an alpha2delta ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCalpha dependent effect.

Authors:  C Boileau; J Martel-Pelletier; J Brunet; D Schrier; C Flory; M Boily; J-P Pelletier
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103

Review 7.  Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.

Authors:  Kathryn J Macdonald; L Trevor Young
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder.

Authors:  Don R Cherek; Oleg V Tcheremissine; Scott D Lane; Cynthia J Pietras
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

9.  Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies.

Authors:  Fatma Sultan Kilic; Basar Sirmagul; Engin Yildirim; Setenay Oner; Kevser Erol
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

10.  Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia.

Authors:  Nisar Ahmad; Fazal Subhan; Nazar Ul Islam; Muhammad Shahid; Naseem Ullah; Rahim Ullah; Muhammad Khurram; Muhammad Usman Amin; Shehla Akbar; Ihsan Ullah; Robert D E Sewell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-07-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.